Table 1 Patient characteristics by SSRI use
| Â | All patients | SSRI use | |
|---|---|---|---|
Non-user | User | ||
Number of patients | 23,669 | 18,885 | 4784 |
Year of diagnosis | |||
 1998–2002 | 5738 (24.2%) | 4491 (23.8%) | 1247 (26.1%) |
 2003–2007 | 8776 (37.1%) | 6911 (36.6%) | 1865 (39.0%) |
 2008–2012 | 9155 (38.7%) | 7483 (39.6%) | 1672 (34.9%) |
Mean age at diagnosis (SD) | 61.9 (14.0) | 62.6 (13.9) | 58.9 (13.9) |
 0–49 | 4774 (20.2%) | 3479 (18.4%) | 1295 (27.1%) |
 50–59 | 5913 (25.0%) | 4590 (24.3%) | 1323 (27.7%) |
 60–69 | 5955 (25.2%) | 4903 (26.0%) | 1052 (22.0%) |
 70–79 | 4037 (17.1%) | 3357 (17.8%) | 680 (14.2%) |
Deprivation quintile | |||
 1 (least deprived) | 6026 (25.5%) | 4923 (26.1%) | 1103 (23.1%) |
 2 | 6087 (25.7%) | 4923 (26.1%) | 1164 (24.3%) |
 3 | 4873 (20.6%) | 3875 (20.5%) | 998 (20.9%) |
 4 | 3941 (16.7%) | 3072 (16.3%) | 869 (18.2%) |
 5 (most deprived) | 2733 (11.6%) | 2084 (11.0%) | 649 (13.6%) |
 Missing (n) | 9 | 8 | 1 |
Comorbidities | |||
 Chronic pulmonary disease | 2716 (11.5%) | 2033 (10.8%) | 683 (14.3%) |
 Diabetes | 1456 (6.2%) | 1141 (6.0%) | 315 (6.6%) |
 Renal disease | 1076 (4.5%) | 914 (4.8%) | 162 (3.4%) |
 Cerebrovascular disease | 650 (2.7%) | 498 (2.6%) | 152 (3.2%) |
 Congestive heart disease | 345 (1.5%) | 287 (1.5%) | 58 (1.2%) |
 Peripheral vascular disease | 264 (1.1%) | 211 (1.1%) | 53 (1.1%) |
 Myocardial infarction | 250 (1.1%) | 199 (1.1%) | 51 (1.1%) |
 Peptic ulcer disease | 238 (1.0%) | 179 (0.9%) | 59 (1.2%) |
 Liver disease | 45 (0.2%) | 35 (0.2%) | 10 (0.2%) |
Hot flushes | 1693 (7.2%) | 1024 (5.4%) | 669 (14.0%) |
Pre-diagnosis confounder medication use | |||
 Hormone replacement therapy | 7002 (29.6%) | 5233 (27.7%) | 1769 (37.0%) |
 Oral contraceptive | 6009 (25.4%) | 4454 (23.6%) | 1555 (32.5%) |
Treatment | |||
 Surgery | 19,218 (81.2%) | 15,212 (80.6%) | 4006 (83.7%) |
 Tamoxifen | 10,051 (42.5%) | 8006 (42.4%) | 2045 (42.7%) |
 Radiotherapy | 8320 (35.2%) | 6683 (35.4%) | 1637 (34.2%) |
 Chemotherapy | 6774 (28.6%) | 5213 (27.6%) | 1561 (32.6%) |
 Aromatase inhibitors | 4975 (21.0%) | 4094 (21.7%) | 881 (18.4%) |
Grade | |||
 1 | 3780 (17.9%) | 2988 (17.8%) | 792 (18.5%) |
 2 | 10,282 (48.7%) | 8210 (48.8%) | 2072 (48.3%) |
 3 | 7039 (33.3%) | 5616 (33.4%) | 1423 (33.2%) |
 4 | 19 (0.1%) | 18 (0.1%) | 1 (0.0%) |
 Missing (n) | 2549 | 2053 | 496 |
Stage | |||
 1 | 4791 (49.0%) | 3812 (48.8%) | 979 (49.7%) |
 2 | 3936 (40.2%) | 3127 (40.0%) | 809 (41.1%) |
 3 | 748 (7.6%) | 623 (8.0%) | 125 (6.4%) |
 4 | 309 (3.2%) | 254 (3.2%) | 55 (2.8%) |
 Missing (n) | 13,885 | 11,069 | 2816 |
Smoking | |||
 No | 12,975 (61.3%) | 10,653 (63.4%) | 2328 (53.2%) |
 Ex | 4677 (22.1%) | 3696 (22.0%) | 976 (22.3%) |
 Yes | 3526 (16.6%) | 2457 (14.6%) | 1068 (24.4%) |
 Missing (n) | 2491 | 2079 | 412 |
Alcohol | |||
 No | 3406 (19.7%) | 2711 (19.7%) | 697 (19.5%) |
 Ex | 347 (2.0%) | 252 (1.8%) | 95 (2.7%) |
 Yes | 13,577 (78.3%) | 10,788 (78.5%) | 2787 (77.9%) |
 Missing (n) | 6339 | 5134 | 1205 |
Obesity | |||
 Normal | 7723 (41.0%) | 6178 (41.5%) | 1548 (39.3%) |
 Overweight | 6326 (33.6%) | 4999 (33.6%) | 1325 (33.6%) |
 Obese | 4776 (25.4%) | 3707 (24.9%) | 1068 (27.1%) |
 Missing (n) | 4844 | 4001 | 843 |